Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s525400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Jia-Qi Lou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Minist…. Hauptthemen laut MEDLINE: Linezolid, Models, Biological, Renal Insufficiency, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Linezolid (LZD), a commonly used antimicrobial agent in clinical practice, has not undergone adequate pharmacokinetic (PK) assessment in pediatric populations with renal impairment (RI). Physiologically based pharmacokinetic (PBPK) modeling provides unique benefits for investigating drug pharmacokinetics in specific patient groups. This study aimed to employ the PBPK model to refine and optimize the therapeutic dosing protocol of LZD for RI pediatric patients.
Methods
The model was developed and validated for both healthy adults and RI adults, which was subsequently adapted for pediatric applications. Upon verification of the pediatric Based on clinical PK data and real-world study findings, the PBPK model demonstrated precise prediction of LZD exposure in pediatric populations with varying degrees of RI, encompassing weight- and age-associated PK variations.
Results
The PBPK modeling simulations exhibited robust agreement with observational data for LZD across both oral and intravenous delivery routes under diverse dosing protocols, as evidenced by the fold error (FE) always between 0.5 and 2 times, geometric mean fold error (GMFE) was less than 2.0 and mean absolute prediction error (MAPE) was within 100%. Pediatric populations with severe or end-stage RI exhibited 1.21-fold and 1.28-fold elevations in plasma concentration-time curve (AUC) values, respectively, relative to healthy pediatric counterparts when administered equivalent 10 mg/kg LZD doses. Pharmacodynamic analysis confirmed that the proposed dosing regimens-8 mg/kg every 8 hours for children with severe or end-stage RI -were effective in achieving the target AUC0-24/MIC ratio of ≥80 at a susceptible inhibitory concentration of ≤ 2 mg/L.
Conclusion
Our model provides a predictive instrument to enhance precision in determining therapeutic LZD dosage regimens for pediatric populations through systematic integration of developmental PK parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Cho…
- Institute of Immunology, Third Military Medical University (Army Medical University), Chongqing, 400038, People's Republic of China.
Zitieren
APA
Lou, J. Q., Huo, B. N., Yang, Y., Wang, S. F., Zhang, L. D., Jia, Y. T., & Song, L. (2025). Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s525400
Vancouver
Lou JQ, Huo BN, Yang Y, Wang SF, Zhang LD, Jia YT, et al. Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s525400
BibTeX
@article{Lou2025,
author = {Lou, Jia-Qi and Huo, Ben-Nian and Yang, Ya and Wang, Shu-Feng and Zhang, Lu-Dan and Jia, Yun-Tao and Song, Lin},
title = {Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s525400}
}
EUVIMED